Dynavax shares rise 14% on promising cancer conference data

“Another abstract from the company showed “encouraging” durability of responses to SD-101 in melanoma, he noted” writes Emma Court for DVAX, -4.82% shares rose 14% in premarket trade Monday after the company released promising data in conjunction with the annual American Association for Cancer Research meeting, happening this week. Dynavax shares have surged 34.8% over the last three months but slumped 0.5% month-to-date, compared with a 4.3% decline in the S&P 500 SPX, -0.29% over the last three months and a 0.6% month-to-date rise.New results for the company’s immuno-oncology drug SD-101 “showed a promising 40% [overall response rate] indicative of potential activity in this difficult-to-treat setting” of head/neck cancers, said RBC Capital Markets analyst Brian Abrahams.

Share This:

Related posts